Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its therapeutic REQORSA in combination with Genentech's Tecentriq in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial standard treatment. The company has previously received two other FTDs for its therapeutic: one for REQORSA in combination with AstraZeneca's Tagrisso in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso, and one for REQORSA in combination with Merck & Co's Keytruda in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda.

Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA

Third FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas , June 28, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company's lead drug candidate, REQORSA® Immunogene Therapy, in combination with Genentech, Inc.'s Tecentriq® in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. In the third quarter of 2023, Genprex expects to enroll the first patient in its Acclaim-3 clinical trial, which is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq for this patient population.

Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options.

Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial

Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.

Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study

Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved forging ahead with the Phase 2 expansion part of the trial.

Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer

Results from Phase 1 Portion Indicate Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas , May 30, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved continuation to the Phase 2 expansion portion of the trial. The combination of REQORSA and osimertinib received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combination with Tagrisso in late-stage non-small cell lung cancer (NSCLC) will be published in an abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, Illinois. "We are thrilled to have our abstract, which reports positive results from the Phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO Annual meeting," said Dr Mark Berger, chief medical officer at Genprex in a statement.

Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed AUSTIN, Texas , May 25, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA® Immunogene Therapy in combination with Tagrisso® in late-stage non-small cell lung cancer (NSCLC) were published in an abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL and online. "We are thrilled to have our abstract, which reports positive results from the Phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO Annual meeting," said Mark Berger, MD, Chief Medical Officer at Genprex.

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting Video Highlights Validation of the ONCOPREX ® Nanoparticle Delivery System with a Second Tumor Suppressor Gene AUSTIN, Texas , May 23, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video where the company's Chief Medical Officer, Mark Berger, MD, discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex's research collaborators. The data were presented at the 2023 American Association of Cancer Research (AACR) annual meeting.

Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 8, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming industry and investor conferences to be held in May 2023. Event: Sidoti Micro Cap Conference Conference Dates: May 10 - 11, 2023 Virtual Presentation: Thursday, May 11 at 12:15 p.m.

Genprex to Participate and Present at Upcoming May Industry and Investor Conferences

Bright Minds Biosciences

Heliogen

Inovio Pharmaceuticals

mCloud Technologies Corp

National CineMedia

NeuroBo Pharmaceuticals Inc

Oncternal Therapeutics Inc

Predictive Oncology Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the company announced. Investors liked what they saw, as shares climbed 5% to $1.

Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise

NPRL2 Gene Therapy Induces Effective Anti-Tumor Activity in Non-Small Cell Lung Cancer Pembrolizumab Resistant Tumors in a Humanized Mouse Model Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene AUSTIN, Texas , April 19, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene (also known as the TUSC4 gene). The studies used the Company's non-viral ONCOPREX® Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models and were presented at the 2023 American Association of Cancer Research (AACR) annual meeting, which took place from April 14-18, 2023 in Orlando, Florida.

Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting

AUSTIN, TX / ACCESSWIRE / April 19, 2023 / On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.

Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases - Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So

Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functions as a novel tumor suppressor for glioblastoma. Genprex CEO Rodney Varner said the research supports the growing body of studies evaluating the tumor suppressor gene TUSC2 as a target in oncology and potentially effective treatment for many types of cancer.

Genprex encouraged by latest reports on novel tumor suppressor

AUSTIN, Texas, April 18, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma. TUSC2 is the tumor suppressor gene that is reexpressed in tumors using REQORSA® Therapy treatment, Genprex's lead drug candidate. Genprex has no affiliation with these researchers.

Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options AUSTIN, Texas , March 23, 2023 /PRNewswire/ -- Rodney Varner, CEO of Genprex, Inc.  ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases. As such, the FDA announced that it will support using biomarkers as substitutes for other biological indicators in gene therapy clinical trials, accelerating the approval process for companies.

Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

Genprex to Present at Bioprocessing Summit Conference

The company's diabetes gene therapy exhibited encouraging preclinical results in both the diabetic mouse model and non-human primate [NHP] model, improving glucose tolerance and reducing insulin requirements. The GPX-002/003 gene therapy could be a long-lasting solution for diabetes, potentially benefiting many patients who require insulin replacement therapy.

Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes AUSTIN, Texas , March 8, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023. Event: 35th Annual Roth Conference Conference Date: March 12-14, 2023 Location: The Ritz-Carlton, Laguna Niguel, Dana Point, California In attendance at the Roth Conference will be Genprex's Chief Financial Officer, Ryan Confer.

Genprex to Participate in March Investor and Industry Conferences

Genprex Inc. said it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for gross proceeds of approximately $4 million.

Genprex announces $4M direct offering with single, healthcare-focused institutional investor

AUSTIN, Texas , Feb. 27, 2023 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and accompanying warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $1.10, will be exercisable immediately and will expire five years from the date of issuance.

Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment. That positive news comes from a trial of gene therapy for the treatment of Type 1 diabetes.

Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data

Genprex, Inc. (NASDAQ:GNPX) has announced that data highlighting the potential of its gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), which started on February 22, 2023, in Berlin, Germany. The Austin, Texas-based clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes, said the abstract data was released, and the presentation will be delivered on February 25 at 2:25 pm CET by Ranjeet Kalsi, a member of the laboratory of George Gittes, from the University of Pittsburgh's Division of Pediatric Surgery, in Pennsylvania.

Genprex unveils groundbreaking data from primate study on its novel gene therapy to treat Type 1 diabetes at ATTD 2023 in Berlin

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline Disruptive gene therapy approach developed by University of Pittsburgh researchers may be a promising treatment for Type 1 and Type 2 diabetes AUSTIN, Texas , Feb. 23, 2023 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany.  The abstract data were released, and the presentation will be delivered on February 25th at 2:25 pm CET by Ranjeet S.

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

News for Genprex Stock (GNPX)